AbbVie encouraged by venetoclax potential for CLL
US drugmaker AbbVie (NYSE: ABBV) has announced that its oral B-cell lymphoma-2 (BCL-2) inhibitor venetoclax has shown high overall response rates in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) with 17p deletion.
The medicine, which is being developed in collaboration with Swiss drug giant Roche’s (ROG: SIX) Genentech unit, is the only one which restores the ability of malignant CLL cells to undergo apoptosis, potentially offering patients the chance of a deep and long-lasting remission.
The Phase II trial data, which has been published in The Lancet Oncology, demonstrated that venetoclax achieved an overall response rate of 79.4%, with 10% complete remission (CR) or complete remission with incomplete recovery of blood counts (CRi) and nodular partial remission (nPR). Complete remission and minimal residual disease negativity was achieved in 18 of the 107 triallists.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze